Search hospitals > California > Los Angeles

Cedars-Sinai Medical Center

Claim this profile
Los Angeles, California 90048
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Pancreatic Cancer
Conducts research for Lung Cancer
Conducts research for Solid Tumors
1450 reported clinical trials
171 medical researchers
Photo of Cedars-Sinai Medical Center in Los AngelesPhoto of Cedars-Sinai Medical Center in Los AngelesPhoto of Cedars-Sinai Medical Center in Los Angeles

Summary

Cedars-Sinai Medical Center is a medical facility located in Los Angeles, California. This center is recognized for care of Breast Cancer, Cancer, Pancreatic Cancer, Lung Cancer, Solid Tumors and other specialties. Cedars-Sinai Medical Center is involved with conducting 1,450 clinical trials across 1,595 conditions. There are 171 research doctors associated with this hospital, such as Leo Mascarenhas, MD, Fataneh (Fae) Majlessipour, Saibal Kar, MD, and Raj Makkar.

Area of expertise

1Breast Cancer
Global Leader
Cedars-Sinai Medical Center has run 104 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
ER positive
2Cancer
Global Leader
Cedars-Sinai Medical Center has run 94 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I

Top PIs

Clinical Trials running at Cedars-Sinai Medical Center

Lung Cancer
Breast Cancer
Skin Cancer
Breast cancer
Crohn's Disease
Kidney Cancer
Non-Hodgkin's Lymphoma
Ovarian Cancer
Cancer
Testicular cancer
Image of trial facility.

Durvalumab

for Lung Cancer

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting2 awards Phase 38 criteria
Image of trial facility.

Ceralasertib + Durvalumab

for Non-Small Cell Lung Cancer

This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting2 awards Phase 310 criteria
Image of trial facility.

Osimertinib + Carotuximab

for Lung Cancer

The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objective response rate, duration of response, progression-free survival, and disease control rate, along with assessing biomarkers through tumor tissue and circulating tumor DNA.
Recruiting2 awards Phase 115 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Cedars-Sinai Medical Center?
Where is Cedars-Sinai Medical Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does Cedars-Sinai Medical Center accept?
What awards or recognition has Cedars-Sinai Medical Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security